Nabriva Refreshes Lefamulin Strategy With New CEO, U.S. Office
This article was originally published in The Pink Sheet Daily
Executive Summary
The Vienna-based biotech looks to U.S. expertise to develop new mechanism-of-action antibacterial in go-it-alone strategy.
You may also be interested in...
Nabriva Wants To Try A Different Approach To Antibiotic Stewardship
Nabriva sees an opportunity for its Phase III antibiotic lefamulin to be used as a first-line agent against community-acquired bacterial pneumonia, rather than being held in reserve, because it targets pathogens that cause lung infections.
European Biotechs Mull Going To Market Without Big Pharma Partners
European biotech companies that have lead products turned down by big pharma are now considering the benefits of taking drugs through late-stage development themselves; more funding options, such as concluding an IPO in the U.S. or Europe, is driving some of this change.
GSK’s First In Class Antibiotic Altabax Has Dosing, Price Advantage
GlaxoSmithKline's topical antibiotic Altabax (retapamulin) will offer a convenience benefit over other topical antibiotics, with less frequent dosing and less than half the treatment period